title: Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.
abstract: OBJECTIVE
  The purpose of this study was to use standard gamble (SG) utility interviews to assess parent preferences for health states of childhood attention-deficit/hyperactivity disorder (ADHD).
  
  
  METHODS
  The study was conducted in August 2003 in London, England. Parents (N=83) of children diagnosed with ADHD completed SG utility interviews, rating their child's current health and 14 hypothetical health states describing untreated ADHD and ADHD treated with a nonstimulant, immediate-release stimulant, or extended-release stimulant. Raw temporary utilities ranging from 0 (worst health) to 1 (best health) were adjusted to a chronic utility scale ranging from 0 (death) to 1 (best health) using a linear transformation. Parents rated the severity of their children's ADHD symptoms using the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS) and their children's health-related quality of life using the EuroQol EQ-5D.
  
  
  RESULTS
  Raw and adjusted SG ratings of hypothetical health states ranged from 0.63-0.90 and 0.88-0.96, respectively. Parents' raw SG scores of their child's current health state (mean=0.72) were significantly correlated with inattentive, hyperactive, and overall ADHD symptoms (r=-0.25, -0.27, -0.27; P <0.05) and the EQ-5D visual analogue scale (r=0.26; P <0.05).
  
  
  CONCLUSIONS
  This UK-based study suggests that parent SG interviews are a valid method for obtaining utilities for child ADHD-related health states. The utilities obtained in this study would be appropriate for use in a cost-utility analysis evaluating the costs and benefits of childhood ADHD treatments in the United Kingdom.
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Secnik_Kristina@lilly.com
authors.forename: Kristina
authors.initials: K
authors.lastname: Secnik
authors.forename: Louis S
authors.initials: LS
authors.lastname: Matza
authors.forename: Suzi
authors.initials: S
authors.lastname: Cottrell
authors.forename: Eric
authors.initials: E
authors.lastname: Edgell
authors.forename: Dominic
authors.initials: D
authors.lastname: Tilden
authors.forename: Sally
authors.initials: S
authors.lastname: Mannix
mesh_terms: D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000145:classification / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002652:Child Behavior / Q000187:drug effects; D005260:Female; D006304:Health Status; D006801:Humans; D008131:London; D008297:Male; D010290:Parents; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D000697:Central Nervous System Stimulants